Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11818MR)

This product GTTS-WQ11818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11818MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11174MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ10660MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ12580MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ12486MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ11442MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ6427MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ11676MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15211MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW